ArticleCureus2025
Tofacitinib-Induced Steroid-Free Remission in Subcutaneous Sarcoidosis With Neurologic Involvement: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of a 62-year-old woman with subcutaneous sarcoidosis and probable neurologic involvement who achieved complete remission with tofacitinib without the use of systemic corticosteroids. The patient presented with multiple firm subcutaneous nodules on the extremities and limb weakness. Skin biopsy demonstrated non-caseating granulomas, and electromyography revealed neurogenic changes consistent with C5-C6 nerve root involvement. Treatment with tofacitinib 5 mg twice daily in combination with methotrexate 7.5 mg weekly led to complete resolution of both cutaneous lesions and neurologic symptoms within two months. Tofacitinib was discontinued after eight months, and remission was sustained at 11-month follow-up. This case illustrates the potential of JAK inhibition as an effective steroid-sparing therapeutic strategy in the management of multisystem sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.